PAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Although some group I PAKs, such as PAK1 and PAK2, have been identified as therapeutic targets in hematologic malignancies, little is understood about the role of PAK6, especially in the context of CML [17,18,19].